495270709568/15/2018 2:03:00 PMThe breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 2:03:00 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
495340710318/15/2018 2:02:33 PMwho are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx630https://www.uhn.ca8/15/2018 2:02:33 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
495272709858/15/2018 2:02:34 PMincluding a synchronous contralateral breast cancer (Note Patients found to have a contralateral breast cancer on study imaging following STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx600https://www.uhn.ca8/15/2018 2:02:34 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
49521816978/15/2018 1:58:40 PMwidespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 1:58:40 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
49521172868/15/2018 1:59:18 PMALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging but is not specific enough to detect a difference across all breast tumor types STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 1:59:18 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
49516074038/15/2018 2:01:11 PMAge ≥18 years (or per national multifocal and/or bilateral early invasive breast cancer are eligible if all Patients with Stage I or IV breast cancer are not eligible STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 2:01:11 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
49523572558/15/2018 1:58:50 PMin Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer HER2-negative, hormone-receptor positive breast cancer that has progressed or STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx330https://www.uhn.ca8/15/2018 1:58:50 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
495084709958/15/2018 2:03:53 PMWith Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 2:03:53 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
49525976348/15/2018 2:00:20 PM15-20% of early breast cancers have high levels of a protein called HER2 which is that, in women receiving treatment for breast cancer, heart edema detected by MRI at STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 2:00:20 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
495095710198/15/2018 2:03:42 PMActivity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer in women with advanced or metastatic ER+ breast cancer, who have disease that has STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0https://www.uhn.ca8/15/2018 2:03:42 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/16/2017 6:07 AM